Equillium to Present at the SVB Leerink 10th Annual Global Healthcare Conference

Rhea-AI Summary

Equillium, Inc. (Nasdaq: EQ) announced its participation in the SVB Leerink 10th Annual Global Healthcare Conference from February 22-26, 2021. The presentation will take place on February 25 at 11:20 AM ET, covering ongoing clinical programs for itolizumab in treating severe autoimmune disorders, including acute graft-versus-host disease and lupus. A live webcast will be available on the company’s website, with an archived replay accessible for 90 days. Equillium focuses on developing innovative treatments for severe immuno-inflammatory diseases.

LA JOLLA, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the SVB Leerink 10th Annual Global Healthcare Conference taking place February 22 – 26, 2021.

Bruce Steel, Equillium’s chief executive officer, and Dolca Thomas, M.D., Equillium’s executive vice president of research and development and chief medical officer, will review each of the ongoing clinical programs in acute graft-versus-host disease, lupus/lupus nephritis and uncontrolled asthma. Mr. Steel, Dr. Thomas and other members of Equillium’s leadership team will be available for one-on-one meetings during the conference.

Date:	Thursday, February 25, 2021
Time:	11:20 AM Eastern Time | 8:20 AM Pacific Time
Location:	Virtual Webcast

A live webcast of the presentation will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/events-and-presentations. An archived replay will be available for 90 days.

About Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.

For more information, visit www.equilliumbio.com.

Investor Contact
Michael Moore
Vice President, Investor Relations & Corporate Communications
+1-619-302-4431
ir@equilliumbio.com

Media Contact
Katherine Carlyle Smith
Senior Account Associate
Canale Communications
+1-805-907-2497
katherine.smith@canalecomm.com

FAQ

When is Equillium's presentation at the SVB Leerink Healthcare Conference?

Equillium's presentation is scheduled for February 25, 2021, at 11:20 AM Eastern Time.

What clinical programs will Equillium discuss at the conference?

Equillium will discuss its ongoing clinical programs for itolizumab, specifically in acute graft-versus-host disease, lupus/lupus nephritis, and uncontrolled asthma.

How can I watch Equillium's presentation live?

You can watch Equillium's presentation live by accessing the webcast on their website under the 'Investors' section.

Will there be a replay of Equillium's conference presentation?

Yes, an archived replay of the presentation will be available for 90 days after the event.

What is itolizumab being developed for by Equillium?

Itolizumab is being developed by Equillium for treating severe autoimmune and inflammatory disorders, including acute graft-versus-host disease and lupus.